Patent · US Active

Organic compounds

US8530522B2 · kind B2 · utility

4Cited by

2References

5Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Guido Jordine · Glückstadt, DE
Michael Mutz · Glückstadt, DE

Key dates

Filing date	Nov 10, 2009
Grant date	Sep 10, 2013
Priority date	—
Expiry date	Mar 31, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.